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Abstract
A prospective study of IgG and IgM isotypes
of anticardiolipin antibodies (aCL) in a series
of 100 patients with systemic lupus erythe-
matosus was carried out. To determine the
normal range of both isotype titres a group of
100 normal control serum samples was studied
and a log-normal distribution of IgG and IgM
isotypes was found. The IgG anticardiolipin
antibody serum was regarded as positive if a
binding index greater than 2-85 (SD 3-77) was
detected and a binding index greater than 4-07
(3.90) was defined as positive for IgM anti-
cardiolipin antibody. Twenty four patients
were positive for IgG aCL, 20 for IgM
aCL, and 36 for IgG or IgM aCL, or both.
IgG aCL were found to have a significant
association with thrombosis and thrombo-
cytopenia, and IgM aCL with haemolytic
anaemia and neutropenia. Specificity and
predictive value for these clinical mani-
festations increased at moderate and high
anticardiolipin antibody titres. In addition, a
significant association was found between
aCL and the presence of lupus anticoagulant.
Identification of these differences in the anti-
cardiolipin antibody isotype associations may
improve the clinical usefulness of these tests,
and this study confirms the good specificity
and predictive value of the anticardiolipin
antibody titre for these clinical manifestations.
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Several recent studies found that patients with
antiphospholipid antibodies (aPL) are prone to
repeated episodes of venous or arterial throm-
bosis, or both,1-11 recurrent fetal loss,8 11-15
and thrombocytopenia.26 8 9 11 15 6In addition,
there have been reports of the possible associa-
tion of aPL with haemolytic anaemia'7 and
neurological events such as cerebrovascular
18 1920accidents, seizures, migraine,'9 and chorea.
Other authors, however, consider that no
association exists and aPL are only an epipheno-
menon.21-23 In fact, few prospective studies of a
large number of unselected patients have been
carried out and no definitive conclusions have
been reached.
Of the various aPL, anticardiolipin anti-
bodies (aCL) have received more attention
owing to their sensitive, reproducible, and
reliable detection by radioimmunoassay3 or
enzyme linked immunosorbent assay (ELISA).24
Several studies suggest that aCL are closely
related to the lupus anticoagulant and the
biological false positive standard tests for
syphilis (BFP-STS).6 Although these antibodies
are not restricted to patients with systemic
lupus erythematosus (SLE), they are often
found in these patients.
Our main objectives were to determine the
prevalence of IgG and IgM anticardiolipin
antibody isotypes in 100 consecutive patients
with SLE in order to compare their possible
association with clinical and laboratory mani-
festations and disease activity.
Patients and methods
PATIENTS
Clinical laboratory features of 100 consecutive
and unselected patients (93 female, seven male)
with SLE were prospectively studied during the
years 1986-1987. All fulfilled four or more of
the 1982 American Rheumatism Association
(ARA) criteria for the classification of SLE.25
DISEASE ACTIVITY AND SUBSETS
Individual SLE clinical features were considered
if they fulfilled the definitions of the ARA
glossary.26
To assess disease activity all records were
evaluated without knowledge of the anticardio-
lipin antibody status. Disease was judged to be
clinically active when the following signs or
symptoms were present: typical dermatitis;
arthritis; serositis; central nervous system
abnormalities (recent onset of chorea, seizures,
psychosis, organic brain syndrome in the absence
of offending drugs or known metabolic derange-
ments, embolic cerebrovascular accidents);
thrombocytopenia (<100x 109/1); haemolytic
anaemia; vasculitis (biopsy); or nephritis (recent
onset of haematuria (>10 red blood cells/high
power field) or casts, or proteinuria >500 mg/
24 h, or a 25% increase in serum creatinine).
Sixty patients were classified as 'active' and 40
as 'inactive' based on these criteria.
Venous or arterial thrombosis, or both, was
diagnosed in 10 patients. Diagnosis of venous
thrombosis (seven patients) was based on clinical
presentation and confirmed by venogram. Two
patients with clinical features of cerebrovascular
accidents or transient ischaemic attacks and
evidence of cerebral infarction on computed
tomographic scans, and two patients with clini-
cal, electrocardiogram, and laboratory evidence
of myocardial infarction were defined as having
arterial thrombosis. None of the 93 women had
a fetal loss during the study. Thrombocytopenia
was present in 16 patients (platelet count
<100x 109/1 on two occasions at least two weeks
apart). Nine patients were considered to have
haemolytic anaemia because they had a fall of at
least 30 g/l in their blood haemoglobin, coinci-
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dent with a rise in unconjugated bilirubin of at
least 10-3 ,tmol/l and a reticulocyte count above
5% at the time of the haemolytic episode. A
positive Coombs' test was not considered essen-
tial, though most patients were tested. Neutro-
penia was present in five patients (neutrophil
count lower than 0 5 x 109/1 on two occasions at
least two weeks apart). Serum samples for the
detection of anticardiolipin antibody were col-
lected during the clinical events.
CONTROLS
The normal control group consisted of 100
healthy blood donors from the blood bank of
the hospital clinic matched for age and sex. All
showed normal coagulation assays and negative
serological test for syphilis.
ANTICARDIOLIPIN ANTIBODY ELISA
Anticardiolipin antibodies were measured by an
ELISA as described by Loizou et al24 and
Gharavi et al27 with minor modifications of our
own. Briefly, the flat bottomed wells of micro-
titre plates (Nunc, Denmark) were coated with
30 il/well of cardiolipin (Sigma) suspended in
ethanol at a concentration of 50 [ig/ml and left to
dry overnight at 4°C. The plates were treated
for non-specific binding by incubation with 110
,ul of 10% fetal calf serum (FCS; Flow) in
phosphate buffered saline (PBS, pH 7-2) solution
for two hours. The wells were then washed four
times with 120 p1 of PBS, and 100 p1 of a 1:100
dilution of the serum in PBS-FCS solution was
added to triplicate test wells; similarly, 100 p1 of
PBS-FCS was added to the blank control wells.
The plates were incubated for one hour at room
temperature. After washing the plates with PBS
100 1tl of a goat antihuman IgG or IgM (Tago
Inc) diluted 1:4000 was added to each well and
incubated for one hour at 37°C. The plates were
washed again with PBS, and 100 tl of alkaline
phosphatase conjugated antibody (rabbit anti-
goat IgG; Sigma) diluted 1:1000 in PBS-FCS
was added to each well. The plates were then
placed in a humidifier incubator at 25°C for one
hour. They were washed with diethanolamine
buffer (pH 9-8), and 100 p1 p-nitrophenyl
phosphate (1 mg/ml) prepared in diethanolamine
immediately before use was added to each well.
The plates were incubated in the dark at room
temperature for one hour. The reaction was
stopped by addition of 3 M NaOH (50 p1) to all
wells and the optical absorbance was read at 405
nm on an ELISA microplate reader (Organon).
Results were expressed as binding index (BI)
calculated from optical absorbance (OA) values
as follows:
BI= OA (test samples)-OA (blank)
OA (referred normal pool)-OA (blank)
COAGULATION ASSAYS
The following tests were carried out in all patients
to detect the lupus anticoagulant according to
the methods previously reported: prothrombin
time, activated partial thromboplastin time,
kaolin clotting time, diluted Russell's viper
venom time, and tissue thromboplastin inhibi-
tion test.28 29 The reagents used were rabbit
brain thromboplastin for prothrombin time and
tissue thromboplastin inhibition test, bovine
thromboplastin for diluted Russell's viper
venom time, and platelet factor 3 plus activator
from rabbit brain tissue for activated partial
thromboplastin time. The positive value for
every coagulative test was defined as 3+ standard
deviations above the mean normal value of the
control group. To rule out a deficit in a
coagulation factor each assay was performed
also with a mixture of patient and control
plasma (1/1, vol/vol). Patients were considered
to have lupus anticoagulant when at least two
assays were positive.
SEROLOGICAL TEST FOR SYPHILIS
A macroscopic rapid plasma reagin (Knicker-
bocker) was used in an 18 mm circle card test.
OTHER LABORATORY STUDIES
Antinuclear antibodies were determined by
indirect immunofluorescence with mouse liver
as substrate. Anti-double-stranded DNA anti-
bodies were determined by Farr's ammonium
sulphate precipitation technique.30 Comple-
ment components (C3, C4) were estimated by
radial immunodiffusion and CH50 by Lachmann
and Hobart's haemolytic technique.3'
STATISTICAL ANALYSIS
Conventional x2 analysis and Fisher's exact test
were used to determine the statistical significance
of clinical and laboratory findings. Stepwise
regression analysis was used to correlate anti-
cardiolipin antibody positivity with 16 variables
(sex, age, SLE activity, cutaneous involvement,
arthritis, serositis, central nervous system
disease, renal involvement, venous or arterial
thrombosis, or both, thrombocytopenia, hae-
molytic anaemia, neutropenia, lymphopenia,
antinuclear antibodies, anti-DNA antibodies,
and complement components) in all patients.
The sensitivity, specificity, and predictive
value of aCL at low, moderate, or high titres for
venous or arterial thrombosis, or both, throm-
bocytopenia, haemolytic anaemia, and neutro-
penia were determined according to the method
of Galen and Gambino.32
Results
ANTICARDIOLIPIN ANTIBODY ISOTYPE
DISTRIBUTION
Study of 100 normal control serum samples
showed a log-normal distribution of both IgG
and IgM anticardiolipin antibody titres (figs 1
and 2). Values were considered normal when
the logarithms of the binding indexes were
below the 98 centile of cumulative normal
distribution. The IgG aCL were regarded as
positive if a binding index greater than 2 85 (SD
3-77) was obtained. A binding index greater
than 4 07 (3 90) was defined as positive for IgM
aCL. When these conventions were used 36
patients were positive for IgG or IgM aCL, or
110
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Figure 1: IgG anticardiolipin antibody distribution in
normal control serum samples.
o.0-
Figure 2: IgM anticardiolipin antibody distribution in
normal control serum samples.
both. The isotype spectra were as follows: 24
patients were positive for IgG aCL and 20 for
IgM aCL. All were arbitrarily divided into three
subgroups consisting of low, moderate, or high
titres of aCL. Only eight patients had both IgG
and IgM aCL (table 1). None of the control sera
was positive for IgG or IgM aCL.
Statistically significant association was found
between the presence of aCL and lupus anti-
coagulant (p=0 01), but not between aCL and
BFP-STS (rapid plasma reagin).
IgG ANTICARDIOLIPIN ANTIBODY
When compared with the 76 patients without
IgG aCL the patients with IgG aCL were found
to have an increased incidence of thrombosis
(p=0 001), thrombocytopenia (p=0 03), and
SLE activity (p=0 005). Stepwise regression
analysis of IgG anticardiolipin antibody titres
with the 16 variables previously described
showed significant correlations with thrombosis
(p=0 001) and thrombocytopenia (p=0 03),
but not with SLE activity.
Table 2 shows the sensitivity, specificity, and
predictive value of the IgG anticardiolipin
antibody test at low, moderate, and high anti-
cardiolipin antibody titres for thrombosis and
thrombocytopenia. At low titre the specificity of
the IgG anticardiolipin antibody test for throm-
bosis and thrombocytopenia was greater than
80%, the sensitivity for thrombosis was 70% and
for thrombocytopenia 47%, but the predictive
values were quite low. At moderate and high
titres, however, the specificity of the test for
both thrombosis and thrombocytopenia varied
from 89% to 96% and its predictive value was in
Table 1: Isotype spectra of anticardiolipin antibody positive
patients
Patient No IgG aCL* IgM aCL
1 +
2 + +++
3 ++ _
4 +
S +++ +++
6 -+++
7 -+++
8 +++
9 ++ +++
10 +
11 ++ -
12 -+++
13 ++ +
14 -
15 - +
16 +
17 -
18 ++
19 -+++
20 +++ +
21 +++
22 - +
23 - +
24 - ++
25 +
26 -+
27 + +++
28 ++ +
29 +++ +++
30 +
31 ++
32 +++-
33 ++
34 ++ -
35 +
36 -
*aCL=anticardiolipin antibodies.
+=low titre (IgG: 2 85-3 29; IgM: 4 07-4-95); ++=moderate
titre (IgG: 3 30-5 05; IgM: 4 96-600); +++= high titre(IgG: :-:5 06; IgM: :-:6-01).
Table 2: Sensitivity, specificity and predictive value of the
IgG anticardiolipin antibody test for thrombosis and
thrombocytopenia
Sensitivity Specificity Predictive value
(%) (%) (%)
A* B* A B A B
Low titre 70 47 81 81 29 33
Moderate titre 50 35 89 89 33 40
High titre 20 18 96 96 33 50
*A=thrombosis; B=thrombocytopenia.
the range 33-50%. Interestingly when the bind-
ing index was -7-93 the predictive values for
thrombosis and thrombocytopenia were 670/o.
IgM ANTICARDIOLIPIN ANTIBODY ASSOCIATIONS
In comparison with the 80 patients without IgM
aCL, those with these antibodies had an
increased incidence of haemolytic anaemia
(p=001) and neutropenia (p=0 005). In
addition, stepwise regression analysis of IgM
anticardiolipin antibody titres with 16 variables
showed significant correlations with haemolytic
anaemia (p=0-015) and neutropenia (p=001).
Table 3 shows sensitivity, specificity, and
predictive value of the IgM anticardiolipin
antibody test at low, moderate, and high anti-
body titres for haemolytic anaemia and neutro-
penia. At moderate and high titres the specificity
of the test for both variables exceeded 80%, the
sensitivity for haemolytic anaemia was 44% and
for neutropenia 60%. When the binding index
was 11 the predictive value for haemolytic
anaemia was 60%, and when the binding index
was 3 15 the predictive value was 100%. In
ill
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Table 3: Sensitivity, specificity and predictive value of the
IgM anticardiolipin antibody test for haemolytic anaemia
and neutropenia
Sensitivity Specificity Predictive value
(%) (%) (%)
A* B* A B A B
Low titre 56 80 84 83 25 20
Moderate titre 44 60 88 87 27 20
High titre 44 60 90 89 31 23
*A=haemolytic anaemia; B=neutropenia.
addition, when the binding index was ¢ 15 the
predictive value for neutropenia was 50%.
OTHER ASSOCIATIONS
Lupus anticoagulant was detected in 30 patients,
and significant association with thrombosis
(p=005) and thrombocytopenia (p=0001) was
found. In addition, BFP-STS (rapid plasma
reagin) was present in 17 cases and no clinical or
biological correlation was found.
Discussion
The need to establish an anticardiolipin antibody
titre for identification of patients with anti-
cardiolipin antibody associated clinical features
is of paramount importance.8 The results of this
study indicate that control and SLE groups
have a non-normal (log-normal) distribution of
anticardiolipin antibody titres. To exclude the
largest number of false positive anticardiolipin
antibody sera only titres greater than 3-77 SD
(binding index ¢2'85) were included for IgG
aCL and greater than 3 90 SD (binding index
¢4 07) for IgM aCL.
The prevalence ofaCL in our population with
SLE is similar to that reported by other
authors' 14 using an ELISA. IgG aCL were
detected in 24% of an unselected group of
patients, IgM aCL in 20%, and either IgG or
IgM aCL in 36%. A much higher prevalence
was found by Harris et al using radioimmuno-
assay.3 The differences in the reported preval-
ences of anticardiolipin antibody positivity may
be due to differences in the sensitivity of the
radioimmunoassay and ELISA techniques, in
the cut off positive level, or may reflect the
effects of patient selection and treatment.
The association of aPL (usually IgG aCL or
lupus anticoagulant) with thrombosis, recurrent
fetal loss, and thrombocytopenia has been
reported in several studies. 1-16 In general, these
studies have determined the antiphospholipid
antibody status of randomly selected patients
with SLE and clinical and laboratory features
recorded by review of their medical charts. In
our prospective study we confirmed the
previously reported association of IgG aCL with
thrombosis and thrombocytopenia. The associa-
tion with recurrent fetal loss, however, was not
examined because no patient had an intrauterine
death during the study. Nevertheless, analysis
of 12 patients from this series with previous
fetal losses (data not included) showed no
association with the anticardiolipin antibody
titre at the moment of the study. In our opinion
the lack of such an association is not surprising.
Firstly, it may be due to the existence of a
variable period of years between the fetal loss
and the determination of the anticardiolipin
antibody titre. Secondly, phospholipids other
than cardiolipin may be related to the recurrent
fetal loss. Thirdly, other antibodies such as anti-
Ro or antilymphocyte may occasionally be
involved in the pathogenesis of fetal losses.33
We found a significant association between
the presence of IgM aCL and haemolytic
anaemia and neutropenia. Although Coombs'
positivity is common in patients with SLE who
have aCL,3 the association with haemolytic
anaemia has previously been recognised only by
Deleze et al'7 and Alarcon-Segovia.34 These
authors consider that aPL may react with the
cell wall of either erythrocytes or platelets and
can cause their destruction either by comple-
ment or by receptor mediated entrapment by
the reticuloendothelial system. Possibly, IgM
aCL would best cause spleen clearance of
erythrocytes and their complement mediated
damage could hence be entertained. A similar
mechanism would cause neutropenia.
No association between aCL and neurological
events other than cerebrovascular accidents was
found in our study. This lack of association may
be due to the small number of patients (14
patients had migraine and two seizures). Never-
theless, both patients with cerebrovascular
accidents had a positive anticardiolipin antibody
titre.
Statistically significant association was found
in our study between the presence of aCL and
lupus anticoagulant, but not between aCL and
BFP-STS. Similar results have been reported
by other authors,35 and they may be due to
differences in phospholipid epitope specificity.6
In conclusion, we observed a high incidence
of aCL in our SLE population and showed a
relation between IgG aCL and thrombosis and
thrombocytopenia and also between IgM aCL
and haemolytic anaemia and neutropenia.
Identification of these differences in the anti-
cardiolipin antibody isotype associations may
improve the clinical usefulness of these tests. In
addition, the findings of this study confirm that
the anticardiolipin antibody titre has a good
predictive value for those clinical manifestations
and may be a good predictor in patients with
SLE.
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